Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb) is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
• The total number of studies reviewed was 2 from systematic reviews/meta-analyses.
• Inmazeb reduced the mortality rate by 17% in subjects with EVD when administered at a 3 ml/kg IV dose. It is preferred over other drugs like ZMapp or Ebanga due to its significant reduction in mortality and lower rate of serious adverse effects.
• In comparison to other treatments such as REGN-EB3 and mAb114 which also reduce mortality but are recommended primarily during future outbreaks, Inmazeb stands out for current use across all age groups including neonates.
• Common adverse effects associated with Inmazeb include fever, tachycardia, diarrhea, vomiting, hypotension, tachypnea, and chills. These side effects are similar across various therapeutic agents used for treating Ebola virus disease (EVD).
• Subgroup considerations highlight that while Ebanga may be an alternative choice particularly suitable for patients with cardiovascular complications due to its specific profile despite higher overall mortality rates compared to Inmazeb.